Colorectal Cancer Screening Amid COVID‐19 in Japan: Analysis From the 2021–2022 JACSIS Study
Cancer Medicine · 2025-04 · 14 (8)
DOI: 10.1002/cam4.70859 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 18.04.2025. Verfasst von Hiroaki Saito und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Health Management, Fukushima Medical University, Fukushima, Japan. Hauptthemen laut MEDLINE: COVID-19, Colorectal Neoplasms, Early Detection of Cancer. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science (JSPS) KAKENHI, the Health Labor Sciences Research Grant.
Abstract (Originalsprache)
Background
Maintaining a high participation rate is crucial for effective colorectal cancer (CRC) screening. The COVID‐19 pandemic placed a significant burden on healthcare facilities, which hindered CRC screening efforts. However, the effects of the prolonged pandemic on CRC screening remain unclear.
Methods
We analyzed data from the Japan COVID‐19 and Society Internet Survey in September 2021 and 2022 to examine CRC screening participation over the past year. We also evaluated the association between CRC screening participation in 2022 and the participation status, future screening intentions, background characteristics, and anxiety about COVID‐19 measured using the fear of coronavirus disease 2019 scale (FVC‐19S) from the 2021 survey..
Results
Of the 13,261 respondents, 40.5% reported undergoing CRC screening in 2021, while 48.7% did so in 2022. Multivariable Poisson regression analysis showed that significant factors associated with CRC screening participation in 2022 included being male (adjusted incidence risk ratio [aIRR] 1.07, 95% confidence interval [CI]; 1.00–1.14, p = 0.026), age in the 40s (aIRR 0.89, 95% CI; 0.81–0.97, p = 0.012) and 50s (aIRR 0.89, 95% CI; 0.82–0.98, p = 0.011), being unmarried (aIRR 0.88, 95% CI; 0.82–0.95, p = 0.001), and employment status such as self‐employed (aIRR 0.86, 95% CI; 0.76–0.97, p = 0.012) or unemployed (aIRR 0.86, 95% CI; 0.81–0.92, p < 0.01). Having an FVC‐19S score below 21 was also a factor (aIRR 0.95, 95% CI; 0.90–1.00, p = 0.032).
Conclusions
Although CRC screening rates increased from 2021 to 2022, a significant proportion of respondents still reported not undergoing screening, highlighting the importance of assessing the long‐term impact of COVID‐19 and identifying factors that make screening less accessible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Health Management, Fukushima Medical University, Fukushima, Japan.
- Department of Internal Medicine, Soma Central Hospital, Soma, Japan.
- Graduate School of Public Health, St. Luke's International University, Chuo-ku, Japan.
- Division of Population Data Science, National Cancer Center Institute for Cancer Control, Tokyo, Japan.
- Breast and Thyroid Center, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan.
- Occupational and Aerospace Psychiatry Group, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
ORCID-Profile: Hiroaki Saito, Akihiko Ozaki
Förderung
- Japan Society for the Promotion of Science (JSPS) KAKENHI
- the Health Labor Sciences Research Grant
Zitieren
APA
Saito, H., Abubakar, A. K., Ozaki, A., Hori, D., Murakami, M., Kaneda, Y., Tsubokura, M., & Tabuchi, T. (2025). Colorectal Cancer Screening Amid COVID‐19 in Japan: Analysis From the 2021–2022 JACSIS Study. Cancer Medicine, 14(8). https://doi.org/10.1002/cam4.70859
Vancouver
Saito H, Abubakar AK, Ozaki A, Hori D, Murakami M, Kaneda Y, et al. Colorectal Cancer Screening Amid COVID‐19 in Japan: Analysis From the 2021–2022 JACSIS Study. Cancer Medicine. 2025;14(8). doi:10.1002/cam4.70859
BibTeX
@article{Saito2025,
author = {Saito, Hiroaki and Abubakar, Aminu Kende and Ozaki, Akihiko and Hori, Daisuke and Murakami, Michio and Kaneda, Yudai and Tsubokura, Masaharu and Tabuchi, Takahiro},
title = {Colorectal Cancer Screening Amid COVID‐19 in Japan: Analysis From the 2021–2022 JACSIS Study},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {8},
doi = {10.1002/cam4.70859}
}
EUVIMED